文献速递结核与非结核分枝杆菌艾滋病与性传播感染

NAT2基因型与成熟度对低出生体重和早产儿(伴或不伴HIV暴露)异烟肼暴露的影响

Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该研究基于57例低出生体重(≤4 kg)和早产儿的群体药代动力学分析,评估口服结核预防时异烟肼的暴露与安全性;发现体重、月经后年龄和NAT2基因型显著影响异烟肼暴露,慢代谢者与快代谢者同剂量下AUC相差5倍,异烟肼在广泛暴露范围内似乎安全。

要点

  • 体重、月经后年龄和NAT2基因型显著影响异烟肼暴露。
  • 同剂量下,NAT2慢代谢者与快代谢者AUC相差5倍。
  • 90%的NAT2成熟在出生后4.4个月达成。

核心结论

  • 在低出生体重/早产儿中,异烟肼剂量需频繁调整以考虑生长和成熟。
  • 基于药物遗传学的给药方案是使所有婴儿获得安全且均等暴露的最有力方法,因为NAT2基因型高度影响异烟肼药代动力学变异。

研究设计与样本

  • 本研究为群体药代动力学分析,纳入出生体重≤4 kg的婴儿(包括早产儿),随访6个月。
  • 药代动力学分析纳入57例婴儿,其中79%为早产儿,84%为低出生体重儿;安全性分析纳入61例婴儿。

主要发现

  • 药代动力学分析纳入57例婴儿,中位(范围)胎龄34(28.7-39.4)周;采样时出生后年龄2.3(0.2-7.3)个月,体重3.7(0.9-9.3)kg。
  • 43例(75.4%)患者有NAT2基因型数据:10例慢代谢者、26例中间代谢者、7例快代谢者。
  • 90%的NAT2成熟在出生后4.4个月达成。
  • 体重、月经后年龄和NAT2基因型显著影响异烟肼暴露,同剂量下慢代谢者与快代谢者AUC相差5倍。
  • 异烟肼在61例安全性分析婴儿的广泛暴露范围内似乎安全。

关键数值与推荐

  • 模拟评估异烟肼暴露和最佳给药方案时使用2个目标:峰浓度(Cmax)3-6 mg/L和曲线下面积(AUC)≥10.52 mg·h/L。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isoniazid (INH) metabolism depends on the N-acetyl transferase 2 (NAT2) enzyme, whose maturation process remains unknown in low birth weight (LBW) and preterm infants. We aimed to assess INH exposure and safety in infants receiving oral tuberculosis prevention. METHODS: This population pharmacokinetics (PK) analysis used INH and N-acetyl-isoniazid (ACL) concentrations in infants (BW ≤ 4 kg), including preterm, with follow-up for 6 months. PK parameters were described using nonlinear mixed effects modeling. Simulations were performed to assess INH exposure and optimal dosing regimens, using 2 targets: Cmax at 3-6 mg/L and area under the curve (AUC) ≥ 10.52 mg h/L. RESULTS: We included 57 infants (79% preterm, 84% LBW) in the PK analysis, with a median (range) gestational age of 34 (28.7-39.4) weeks. At the time of sampling, postnatal age was 2.3 (0.2-7.3) months and weight (WT) was 3.7 (0.9-9.3) kg. NAT2 genotype was available in 43 (75.4%) patients (10 slow, 26 intermediate, and 7 fast metabolizers). Ninety percent of NAT2 maturation was attained by 4.4 post-natal months. WT, postmenstrual age, and NAT2 genotype significantly influenced INH exposure, with a 5-fold difference in AUC between slow and fast metabolizers for the same dose. INH appeared safe across the broad range of exposure for 61 infants included in the safety analysis. CONCLUSIONS: In LBW/preterm infants, INH dosing needs frequent adjustment to account for growth and maturation. Pharmacogenetics-based dosing regimens is the most powerful approach to deliver safe and equalized exposures for all infants, because NAT2 genotype highly impacts INH pharmacokinetic variability.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Béranger A, Bekker A, Solans BP, et al. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. Clin Infect Dis. 2022. PMID: 35134861. doi:10.1093/cid/ciac001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。